KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Leases (2019 - 2024)

Historic Leases for Pfizer (PFE) over the last 6 years, with Q4 2024 value amounting to $2.3 billion.

  • Pfizer's Leases fell 2171.68% to $2.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 billion, marking a year-over-year decrease of 2171.68%. This contributed to the annual value of $2.3 billion for FY2024, which is 2171.68% down from last year.
  • According to the latest figures from Q4 2024, Pfizer's Leases is $2.3 billion, which was down 2171.68% from $2.9 billion recorded in Q4 2023.
  • Pfizer's 5-year Leases high stood at $3.0 billion for Q4 2022, and its period low was $1.4 billion during Q4 2020.
  • Moreover, its 5-year median value for Leases was $2.8 billion (2021), whereas its average is $2.5 billion.
  • Per our database at Business Quant, Pfizer's Leases soared by 10483.41% in 2021 and then tumbled by 2171.68% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Leases stood at $1.4 billion in 2020, then skyrocketed by 104.83% to $2.8 billion in 2021, then rose by 5.74% to $3.0 billion in 2022, then fell by 2.6% to $2.9 billion in 2023, then decreased by 21.72% to $2.3 billion in 2024.
  • Its Leases stands at $2.3 billion for Q4 2024, versus $2.9 billion for Q4 2023 and $3.0 billion for Q4 2022.